YOLFTbeta
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

603707 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

8.47CNY-0.01 (-0.12%)

Price History

Full chart

Market Stats

Previous Close8.48
Open8.40
Day Range8.33 – 8.49
52-Week Range6.72 – 10.56
Volume12.90M
Market Cap13.23B
P/E (TTM)27.30
Forward P/E0.00
EPS0.30
Dividend Yield1.22%
Beta0.36
50-Day Avg7.92
200-Day Avg8.72

About

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injection, liraglutide injection, daptomycin for injection, pantoprazole sodium for injection, reganoxone injection, leucovorin calcium for injection, bivalirudin for injection, micafungin for injection, ducalciferol injection, fondaparinux sodium injection, and cisatracurium besylate injection. In addition, the company offers process development and preparation, process optimization, registration and validation approval, and manufacturing, as well as customized research and development, and manufacturing for commercialization. Its injection products are used in anticoagulation, anti-tumor, and cardiovascular disease areas, surgical anesthesia, antibacterial infection, and contrast imaging. The company was founded in 2000 and is based in Nanjing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Tang Yongqun
  • Employees1.56K
  • HeadquartersNo. 16 Xuefu Road, Nanjing, China, 210032, China
  • Websitehttps://www.nkf-pharma.com

Leadership

  • Mr. Tang YongqunGM & Chairman · b. 1976
  • Xiaomei GuAccounting Supervisor

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue499.82M416.12M468.73M581.91M1.11B1.70B2.47B2.91B3.69B3.71B3.93B3.92B3.99B
Growth (%)--16.75%+12.64%+24.15%+91.22%+52.81%+45.25%+18.03%+26.48%+0.71%+5.89%-0.20%+1.71%
Cost of Revenue367.89M326.23M340.09M337.01M596.68M859.96M1.20B1.24B1.60B1.78B3.27B2.11B2.42B
Gross Profit131.93M89.89M128.64M244.91M516.04M840.37M1.27B1.68B2.08B1.93B659.14M1.81B1.57B
Gross Margin26.39%21.60%27.44%42.09%46.38%49.42%51.24%57.60%56.51%52.10%16.77%46.17%39.41%
Operating Expense52.18M30.62M30.05M83.83M163.60M379.94M597.70M802.02M901.41M760.95M953.85M817.18M991.20M
Operating Income79.74M59.28M98.59M161.08M352.44M460.43M667.64M876.98M1.18B1.17B-294.71M994.33M581.37M
Operating Margin15.95%14.24%21.03%27.68%31.67%27.08%27.03%30.09%32.06%31.61%-7.50%25.34%14.57%
EBITDA86.32M57.60M87.69M181.34M382.26M491.23M717.39M1.01B1.32B1.16B-178.25M1.14B997.65M
EBITDA Margin17.27%13.84%18.71%31.16%34.35%28.89%29.05%34.74%35.94%31.27%-4.53%28.94%25.00%
Net Income70.32M50.49M87.55M257.24M314.22M424.55M604.96M806.12M1.06B1.09B-189.45M826.14M581.54M
Net Income Margin14.07%12.13%18.68%44.21%28.24%24.97%24.50%27.66%28.73%29.38%-4.82%21.06%14.57%
R&D-24.17M27.88M49.05M77.19M101.18M166.35M187.53M220.95M263.66M372.29M329.92M348.13M
R&D as % of Total Revenue-5.81%5.95%8.43%6.94%5.95%6.74%6.43%5.99%7.10%9.47%8.41%8.72%
Interest Expense7.19M4.59M5.33M1.88M4.78M9.58M23.26M60.72M94.14M59.67M81.05M78.04M55.25M
Interest Expense % of Total Revenue1.44%1.10%1.14%0.32%0.43%0.56%0.94%2.08%2.55%1.61%2.06%1.99%1.38%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.16B1.54B1.30B1.52B2.69B3.40B5.08B7.72B8.22B10.01B9.52B9.51B10.34B
Total Liabilities138.91M508.26M204.72M208.09M642.50M981.21M2.07B3.98B2.81B3.84B3.73B3.02B3.44B
Total Equity1.02B1.03B1.09B1.31B2.05B2.42B2.97B3.72B5.38B6.17B5.80B6.49B6.90B
Cash310.33M594.35M432.42M265.69M73.13M434.80M364.16M493.55M658.55M1.39B1.21B1.02B1.39B
Total Debt87.10M392.80M101.06M119.96M322.88M319.95M1.37B3.26B2.05B2.96B2.09B2.06B-
Net Debt-223.22M-201.55M-331.36M-145.73M249.75M-114.86M1.00B2.76B1.39B1.58B876.43M1.04B49.90M

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow193.91M178.74M137.28M-286.79M-234.59M62.37M-841.38M-565.85M683.63M595.45M1.62B1.50B1.18B
Investing Cash Flow-44.45M-220.36M53.24M139.54M-592.93M204.25M-153.62M-1.17B170.14M-400.50M-1.18B-910.73M-
Financing Cash Flow-132.81M-24.20M-8.57M-19.04M623.65M-55.82M951.38M1.97B-912.39M-310.81M51.20M-731.28M-
Capital Expenditure61.96M29.40M24.87M72.51M81.14M82.76M115.41M294.36M440.76M470.08M419.07M506.82M560.15M
Free Cash Flow131.96M149.34M112.41M-359.30M-315.72M-20.39M-956.79M-860.21M242.87M125.37M1.20B994.41M622.64M
Dividends Paid48.65M40.23M31.49M37.95M3.00M73.10M82.90M215.57M140.41M186.59M248.47M213.19M218.42M
FCF to OCF68.05%83.55%81.88%125.28%134.59%-32.70%113.72%152.02%35.53%21.05%74.12%66.24%52.64%
Dividend Paid to FCF36.87%26.94%28.01%-10.56%-0.95%-358.46%-8.66%-25.06%57.81%148.83%20.70%21.44%35.08%

Earnings

Report DateOct 15, 2017Jan 27, 2018Apr 17, 2018Jul 19, 2018Oct 16, 2018Dec 31, 2018Apr 25, 2019Jul 31, 2019Oct 28, 2019Apr 30, 2020Jul 30, 2020Oct 9, 2020Apr 26, 2021Aug 2, 2021Oct 29, 2021Apr 26, 2022Aug 29, 2022Oct 28, 2022Apr 27, 2023Apr 28, 2025Aug 28, 2025Sep 30, 2025Dec 31, 2025Apr 29, 2026Aug 27, 2026
EPS Estimate-------------------0.130.130.240.260.090.15
EPS Actual0.060.060.080.070.070.060.090.090.100.170.210.130.210.230.170.210.180.180.110.050.130.090.090.050.07
Surprise--------------------61.54%0.00%-62.50%-65.38%-44.44%-53.33%
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market--Pre-marketPre-market

Key Statistics & Ratios

Market Cap13.23B
Enterprise Value11.91B
Trailing P/E27.30
Forward P/E0.00
Price / Sales3.36
Price / Book1.84
EPS0.30
Book Value4.23
Revenue (TTM)3.94B
Gross Profit (TTM)1.63B
EBITDA823.41M
Profit Margin12.26%
Operating Margin10.48%
Return on Equity7.13%
Return on Assets3.58%
Shares Outstanding1.62B
Shares Float440.55M
Beta0.36
Dividend Yield1.22%
Dividend Rate0.10
Payout Ratio33.33%

Dividends

20231×
0.12Jul 7, 2023
20221×
0.15Jul 11, 2022
20211×
0.12Jul 15, 2021
20201×
0.18Jul 23, 2020
20191×
0.07Jul 10, 2019
20181×
0.05Apr 3, 2018

Stock Splits

  • Jul 11, 202213:10
  • Jul 15, 202113:10
  • Jul 23, 202013:10
  • Jul 10, 201913:10
  • Apr 3, 201813:10